The FDA has approved orlistat (Xenical, Hoffmann-La Roche, Nutley, NJ) for obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet. The product is also indicated to reduce the risk for weight regain after weight loss. It is indicated for obese patients with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, or dyslipidemia).
Nightingale SL. Orlistat Approved for Obesity. JAMA. 1999;281(21):1978. doi:10.1001/jama.281.21.1978
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: